Learn More
PURPOSE To define cardiovascular (CV) risk and reversibility of cardiac events in patients who received sunitinib versus comparator treatment (interferon-alfa or placebo). PATIENTS AND METHODS We(More)
e13607^ Background: Abnormalities of the Rho family pathway are involved in different steps of malignant transformation and tumor progression. Of the many effector proteins that bind to active Rho(More)